Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q4 2024 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed picture: strong revenue growth and a robust share repurchase program are positives, but increased operational costs, economic pressures, and lackluster synergy realization pose challenges. The Q&A session highlights uncertainties about future synergies and market dynamics. Despite a solid financial performance, the lack of clear guidance on key issues tempers optimism. Considering the company's small-cap status, the stock price is likely to remain stable, with potential fluctuations balanced by both positive and negative factors.
Key Financial Performance
Net Product Revenues (Q4 2024) $181.9 million, up 22% year-over-year.
Net Product Revenues (Full Year 2024) $631.4 million, up 11% year-over-year.
Jornay Net Revenue (Q4 2024) $29.3 million, first full quarter of ownership.
Jornay Pro Forma Net Revenue (Full Year 2024) $100.7 million, inclusive of $37.2 million recognized by Collegium.
Belbuca Net Revenue (Q4 2024) $55.2 million, up 12% year-over-year.
Belbuca Net Revenue (Full Year 2024) $211.3 million, up 16% year-over-year.
Xtampza ER Net Revenue (Q4 2024) $51.5 million, up 6% year-over-year.
Xtampza ER Net Revenue (Full Year 2024) $191.3 million, up 8% year-over-year.
Nucynta Franchise Net Revenue (Q4 2024) $41.8 million, down 11% year-over-year.
Nucynta Franchise Net Revenue (Full Year 2024) $176.5 million, down 7% year-over-year.
GAAP Operating Expenses (Q4 2024) $60.2 million, up 83% year-over-year.
GAAP Operating Expenses (Full Year 2024) $207.4 million, up 30% year-over-year.
Non-GAAP Adjusted Operating Expenses (Q4 2024) $51.1 million, up 97% year-over-year.
Non-GAAP Adjusted Operating Expenses (Full Year 2024) $150.6 million, up 22% year-over-year.
GAAP Net Income (Q4 2024) $12.5 million, compared to $31.9 million in Q4 2023.
GAAP Net Income (Full Year 2024) $69.2 million, compared to $48.2 million in 2023.
Non-GAAP Adjusted EBITDA (Q4 2024) $107.7 million, up 3% year-over-year.
Non-GAAP Adjusted EBITDA (Full Year 2024) $401.2 million, up 9% year-over-year.
GAAP Earnings Per Share (Q4 2024) $0.39 basic and $0.36 diluted, compared to $0.99 basic and $0.82 diluted in Q4 2023.
GAAP Earnings Per Share (Full Year 2024) $2.14 basic and $1.86 diluted, compared to $1.43 basic and $1.29 diluted in 2023.
Non-GAAP Adjusted Earnings Per Share (Q4 2024) $1.77, compared to $1.58 in Q4 2023.
Non-GAAP Adjusted Earnings Per Share (Full Year 2024) $6.45, compared to $5.47 in the prior year.
Cash, Cash Equivalents, and Marketable Securities (End of 2024) $162.8 million.
Share Repurchases (2024) $60 million, including $25 million in Q4 2024.
Net Leverage (End of 2024) Less than two times.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Jornay PM Growth: Jornay prescriptions grew 29% year-over-year and 11% quarter-over-quarter in Q4 2024, with pro forma net revenue expected to exceed $135 million in 2025.
Pain Portfolio Revenue: The pain portfolio generated 5% revenue growth in 2024, led by record revenues for BELBUCA and Xtampza ER.
Belbuca Performance: Belbuca achieved record net revenue of $55.2 million in Q4 2024, up 12% year-over-year.
Xtampza ER Performance: Xtampza ER net revenue reached a record $51.5 million in Q4 2024, up 6% year-over-year.
Market Expansion for Jornay: Collegium plans to expand its sales force from 125 to 180 representatives to increase awareness and adoption of Jornay among healthcare professionals.
ADHD Market Growth: The ADHD market has been growing at an average rate of 6% from 2019 to 2024, with Jornay positioned to capture significant market share.
Operational Efficiency: Collegium achieved financial guidance for 2024, growing total revenue by 11% and adjusted EBITDA by 9%.
Share Repurchase Program: Collegium repurchased $60 million worth of shares in 2024, with $90 million remaining in the share repurchase program.
Strategic Acquisition: The acquisition of Ironshore Therapeutics positions Collegium to leverage its expertise and drive growth in neuropsychiatry.
Capital Deployment Strategy: Collegium is focused on strategically deploying capital to create shareholder value, including investments in Jornay and business development.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Commercialization Risks: There is a risk that Collegium may not be able to successfully commercialize its products, which could lead to significant expenses without corresponding revenue.
Litigation Risks: The company may not prevail in current or future litigation pertaining to its business, which could adversely affect its financial position.
Regulatory Risks: The company faces regulatory risks that could impact its ability to operate effectively and introduce new products to the market.
Supply Chain Challenges: Potential supply chain challenges could affect the availability and distribution of products, impacting revenue generation.
Competitive Pressures: The ADHD market is highly competitive, with significant pressure from established stimulant medications, which could hinder Jornay's market penetration.
Economic Factors: Economic factors, such as patient deductible resets and out-of-pocket costs, may lead to a decline in prescriptions and revenue in the first quarter.
Operational Costs: Increased operational costs associated with the acquisition of Jornay may impact profitability in the short term.
Market Access Issues: Despite strong market access coverage, any changes in insurance coverage or reimbursement policies could affect product sales.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Ironshore Acquisition: Collegium acquired Ironshore Therapeutics, establishing a new presence in neuropsychiatry with its lead medicine Jornay PM.
Jornay Growth Strategy: Collegium aims to drive significant growth in Jornay, targeting increased awareness among healthcare professionals, patients, and caregivers.
Pain Portfolio Maximization: The company plans to maximize its pain portfolio, which generates durable cash flows and has a longer revenue stream.
Capital Deployment: Collegium is focused on strategically deploying capital to create shareholder value, including business development and share repurchase programs.
2025 Revenue Guidance: Collegium expects net product revenues in the range of $735 million to $750 million for 2025, primarily driven by Jornay.
Jornay Revenue Projection: Jornay is expected to generate net product revenues in excess of $135 million in 2025.
Adjusted EBITDA Guidance: Adjusted EBITDA is projected to be in the range of $435 million to $450 million for 2025.
Operating Expenses Guidance: Adjusted operating expenses are expected to be in the range of $220 million to $230 million for 2025.
Debt and Leverage: Collegium aims to end 2025 with net leverage of less than one time.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Program: In 2024, Collegium Pharmaceuticals repurchased $60 million worth of shares, including $25 million in the fourth quarter and $35 million through an accelerated share repurchase program in May 2024. There remains $90 million authorized for share repurchases through Q2 of 2025.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Could you perhaps lay out any sort of path that you envision for Collegium over the next three to five years?
A:Our strategy for long-term growth is a function of both organic growth as well as inorganic. We are looking at commercial assets that can add meaningful revenue in the near term, particularly in ADHD and CNS areas.
Q:Could you quantify any synergies that you have been — that you’ve had realized from the integration of Ironshore?
A:We achieved typical synergies such as senior management overlap and G&A type synergies, but they were not a meaningful consideration as part of the deal.
Q:In regards to the NOPAIN Act, are there any dynamic shifts to the pain treatment category that you’d expect?
A:The NO PAIN Act had no impact on our portfolio positively or negatively, as it primarily focuses on inpatient settings.
Q:What portion of ADHD prescribers or volumes does the expanded sales force encompass?
A:The expanded sales force will cover 60% of the long-acting market, targeting about 23,000 physicians.
Q:How are you thinking about the need for further expansion of the sales organization?
A:We will look at coverage every year, but we don’t anticipate significant growth in the sales force.
Q:How are you planning for loss of exclusivity for BELBUCA and NUCYNTA?
A:There is no party that has the necessary combination of ingredients to launch competitive generics against our pain portfolio. The LOE dates for Nucynta are July 2027 for ER and January 2027 for IR.
Q:Review of Unclear Management Responses
A:Management did not provide a direct answer regarding the specific synergies realized from the integration of Ironshore, stating they were not a meaningful consideration. Additionally, the response to the NOPAIN Act lacked clarity on any potential future impacts.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ADHD
Belbuca
HCPs
Ironshore
Vikram
awareness
brand
care professional
day
durability Nucynta
dynamic reset
health care
investment term
majority
medication
medicine treatment
momentum driver
momentum investment
need
opportunity
patient caregiver
phase Collegium
portfolio cash
portfolio medicine
potential investment
prescribers
prescription change
priority
profile
program debt
request
research
sale force
shareholder value
stream
symptom control
work
COLL Transcript
Collegium Pharmaceutical, Inc. (COLL) Q3 2025 Earnings Call Transcript
Positive11-6
The company reported record high revenue and strong earnings, coupled with optimistic guidance and a raised financial outlook. Despite some uncertainties in strategic execution and M&A specifics, the market is likely to react positively due to robust financial performance, a significant share repurchase program, and strategic growth initiatives. Given the company's small-cap status, these factors are expected to drive a positive stock price movement in the short term.
Collegium Pharmaceutical, Inc. (COLL) Q2 2025 Earnings Call Transcript
Positive8-7
The earnings call shows strong financial performance with record revenue growth and optimistic guidance, particularly for Jornay PM. The new $150 million share repurchase program and debt repayment plan further enhance investor confidence. Despite increased operating expenses, the company's strategic focus on expanding market reach and awareness, especially among adults, is promising. The Q&A session did not reveal significant risks, and analysts seemed satisfied with management's responses. Considering the company's small-cap status, the positive developments are likely to result in a stock price increase of 2% to 8% over the next two weeks.
Collegium Pharmaceutical, Inc. (COLL) Q1 2025 Earnings Call Transcript
Unknown5-9
The earnings call presents a mixed outlook. While financial performance shows growth, the decline in GAAP net income and EPS, alongside high operating expenses, raises concerns. The positive shareholder return plan and acquisition strategy are offset by competitive pressures and economic uncertainties highlighted in the Q&A. The market cap suggests moderate volatility, but the lack of clear guidance on key strategic initiatives tempers expectations. Overall, the sentiment is neutral given the balanced positives and negatives.
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q4 2024 Earnings Call Transcript
Unknown2-28
The earnings call presents a mixed picture: strong revenue growth and a robust share repurchase program are positives, but increased operational costs, economic pressures, and lackluster synergy realization pose challenges. The Q&A session highlights uncertainties about future synergies and market dynamics. Despite a solid financial performance, the lack of clear guidance on key issues tempers optimism. Considering the company's small-cap status, the stock price is likely to remain stable, with potential fluctuations balanced by both positive and negative factors.
COLL Slides
COLL Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
